Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AC Immune, Amerisourcebergen, Celsion, Cytrx, Lipocine, Navigo, Novavax, Outlook, Sciwind, Seagen, Synerk, Zai.
Valneva SE is approaching a crucial point with its troubled efforts to develop a COVID-19 vaccine, having announced Sept. 26 it’s in talks with a potential partner for its next-generation jab. The company cautioned the negotiations could take several months and may not succeed. The company’s problems with its COVID-19 vaccine, which is based on an inactivated whole virus, have weighed on its shares (Paris:VLA), which collapsed from a 52-week high of more than €29 (US$28.29) in December 2021 to €5.74 at the close of trading Sept. 26.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amniotics, Avenue, Bausch + Lomb, Biontech, Ferring, Glenmark, Infant Bacterial, Oncopeptides, Pfizer, Rebiotix, Spectrum.
As doctors and public health officials brace for a possible fall coronavirus surge, one of the challenges continues to be predicting who will have a mild, moderate or severe case of COVID-19.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allogene, Aqualung, Chia Tai-Tianqing, Ensysce, Inventiva, Marinus, Pfizer, Plus, Servier, Sino, South Rampart, Tonix.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbvie, Alligator, Alnylam, Antengene, Aptevo, Artiva, Astrazeneca, Beigene, Bluebird, Bristol Myers Squibb, Cyxone, First Wave, Genentech, Heron, Leo, Medexus, Psyence, Roche, Seagen, Xortx.
President Joseph Biden’s recent statement that the COVID-19 pandemic is over may or may not reflect popular fatigue with the associated public health emergency (PHE), but the statement struck a different tone in some quarters on Capitol Hill. Sen. Richard Burr (R-N.C.) was one of several who argued that the need for the PHE had thus necessarily run its course, with Burr specifically calling into question the need for additional funding for COVID-related federal health efforts.
RSS
